← Leaderboards
Paul Trippier
University Of Nebraska Medical Center
$6,285,040
Attributed
$9,150,124
Total exposure
5
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.7M · FY2018–25$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,150,124 · 5
By mechanism
R01$8,168,599 · 3
T32$802,122 · 1
R21$179,403 · 1
Top collaborators
- Thomas J Abbruscato6 shared
- Vardan T. Karamyan6 shared
- Howard S. Fox4 shared
- Bin Duan1 shared
Most similar at University Of Nebraska Medical Center
Same institution · by research overlap
- Megan E Bosch$67,181
- Bin Duan$1,739,996
Others in their field
Other Emerging Leaders on “Drug Discovery”
- Leonard Freedman · Leidos Biomedical Research, Inc.$255,277,443
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Lynn Briscoe · Leidos Biomedical Research, Inc.$93,294,869
- John Damon Chodera · Sloan-Kettering Inst Can Research$64,994,606
- Leonard Freedmand · Leidos Biomedical Research, Inc.$52,916,621
- Gary Kobinger · University Of Texas Med Br Galveston$41,631,815
Research focus
Drug DiscoveryPropertyPharmaceutical PreparationsIn VivoDrug KineticsLeadSmall MoleculeMouse ModelLibrariesDesignPharmacologyStructureIn VitroScaffoldToxic EffectReportingChildhoodChildEnzymesOverexpressionProductionBaseCellsApoptosis
Grant awards (24)
Development and Characterization of Small Molecule Activators of Peptidase Neurolysin for Stroke Therapy$645,589
R01 · FY2025 · NS
Small Molecule Drug Discovery for CLN3 and CLN6 Disease$503,579
R01 · FY2025 · HD · contact PI
Flupirtine Analogue Synthesis and Screening for the Treatment of Chemotherapy-Induced Neuropathic Pain$179,403
R21 · FY2025 · CA
UNMC Training Program in Alzheimerâs Disease and Related Dementias Drug Discovery$169,358
T32 · FY2025 · AG · contact PI
Small Molecule Drug Discovery for CLN3 and CLN6 Disease$503,500
R01 · FY2024 · HD · contact PI
UNMC Training Program in Alzheimerâs Disease and Related Dementias Drug Discovery$261,510
T32 · FY2024 · AG · contact PI
Small Molecule Drug Discovery for CLN3 and CLN6 Disease$514,561
R01 · FY2023 · HD · contact PI
AKR1C3 Inhibitors as Chemotherapeutic Potentiators$375,590
R01 · FY2023 · CA · contact PI
UNMC Training Program in Alzheimerâs Disease and Related Dementias Drug Discovery$208,513
T32 · FY2023 · AG · contact PI
Development and Characterization of Peptidomimetic Small Molecule Activators of Peptidase Neurolysin for Stroke Therapy$578,588
R01 · FY2022 · NS
Small Molecule Drug Discovery for CLN3 and CLN6 Disease$522,114
R01 · FY2022 · HD · contact PI
AKR1C3 Inhibitors as Chemotherapeutic Potentiators$375,548
R01 · FY2022 · CA · contact PI
UNMC Training Program in Alzheimerâs Disease and Related Dementias Drug Discovery$162,741
T32 · FY2022 · AG · contact PI
AKR1C3 Inhibitors as Chemotherapeutic Potentiators$49,683
R01 · FY2022 · CA · contact PI
Development and characterization of peptidomimetic small molecule activators of peptidase neurolysin for stroke therapy.$578,745
R01 · FY2021 · NS
Small Molecule Drug Discovery for CLN3 and CLN6 Disease$540,353
R01 · FY2021 · HD · contact PI
AKR1C3 Inhibitors as Chemotherapeutic Potentiators$414,159
R01 · FY2021 · CA · contact PI
Development and characterization of peptidomimetic small molecule activators of peptidase neurolysin for stroke therapy.$578,745
R01 · FY2020 · NS
AKR1C3 Inhibitors as Chemotherapeutic Potentiators$383,710
R01 · FY2020 · CA · contact PI
AKR1C Inhibitors as Chemotherapeutic Potentiators$30,141
R01 · FY2020 · CA · contact PI
Development and characterization of peptidomimetic small molecule activators of peptidase neurolysin for stroke therapy.$578,745
R01 · FY2019 · NS
AKR1C3 Inhibitors as Chemotherapeutic Potentiators$286,787
R01 · FY2019 · CA · contact PI
AKR1C3 Inhibitors as Chemotherapeutic Potentiators$107,392
R01 · FY2019 · CA · contact PI
Development and characterization of peptidomimetic small molecule activators of peptidase neurolysin for stroke therapy.$601,070
R01 · FY2018 · NS